γδ T cells in cancer

Detalhes bibliográficos
Autor(a) principal: Coffelt, Seth B.
Data de Publicação: 2020
Outros Autores: Kabelitz, Dieter, Silva-Santos, Bruno, Kuball, Jurgen, Born, Willi, Bank, Ilan
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/47254
Resumo: Copyright © 2020 Coffelt, Kabelitz, Silva-Santos, Kuball, Born and Bank. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
id RCAP_eb8af74486f913469535b5cc6aa6fb8f
oai_identifier_str oai:repositorio.ul.pt:10451/47254
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling γδ T cells in cancerBisphoshonatesButyrophilinCancerImmunotherapyγδ T cellsCopyright © 2020 Coffelt, Kabelitz, Silva-Santos, Kuball, Born and Bank. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Since the discovery of gd T cells, this rare and unique component of the immune system has been recognized for its potential in cancer immunology and immunotherapy. In the mid-1980s, it became clear that a major component of adaptive immune responses is the ability of T cell receptors (TCR) to undergo somatic recombination in order to recognize multiple antigens. TCRs consisting of either ab and gd chains were discovered in rapid succession (1–6). An important observation was made in these initial studies: gd T cells stimulated through their TCR are able to kill cancer cells (2). Over these past decades, researchers have learned that gd T cells share many similarities with ab T cells, as well as major differences. However, discoveries in gd T cell biology have failed to keep the same pace as ab T cell biology. The molecular targets of gdTCRs and functions of these cells have largely eluded researchers, partly because gd T cell recognition of cancer cells and their response kinetics are very different to ab T cells (7, 8). Recent years have seen major advances in gd T cell biology and established the non-redundancy of this lymphocyte subset, particularly in the context of cancer (9–11). gd T cells are being used as cellular vehicles to target tumors and prognostic indicators of cancer progression. The aim of the articles collected in this Research Topic is to describe new developments and approaches to enhance the anti-tumor functions of gd T cells, and to discuss how expression of their ligands can assist with prognosis of cancer patients.The authors acknowledge funding from the Cancer Research UK Glasgow Centre (A25142 to SBC), the Wellcome Trust (208990/Z/17/Z to SBC), the Medical Research Council (MR/R502327/1 to SBC), Breast Cancer Now (2018JulPR1101 and 2019DecPhD1349 to SBC), Tenovus Scotland (S17-17 to SBC), the Deutsche Forschungsgemeinschaft (Ka 502/19-2 to DK), the Wilhelm Sander Foundation (2018.045.1 to DK), “la Caixa” Banking Foundation (HR18-00069 to BS-S), the Dutch Research Council (NWO ZonMW 43400003 to JK), the Dutch Cancer Society (KWF UU 2014-6790, UU 2015-7601, UU 2018-11393, UU 2018-11979, UU 2019-12586, UU 2020-13043 to JK).FrontiersRepositório da Universidade de LisboaCoffelt, Seth B.Kabelitz, DieterSilva-Santos, BrunoKuball, JurgenBorn, WilliBank, Ilan2021-04-06T12:46:40Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/47254engFront Immunol. 2020 Nov 20;11:60241110.3389/fimmu.2020.6024111664-3224info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:50:03Zoai:repositorio.ul.pt:10451/47254Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:59:20.047534Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv γδ T cells in cancer
title γδ T cells in cancer
spellingShingle γδ T cells in cancer
Coffelt, Seth B.
Bisphoshonates
Butyrophilin
Cancer
Immunotherapy
γδ T cells
title_short γδ T cells in cancer
title_full γδ T cells in cancer
title_fullStr γδ T cells in cancer
title_full_unstemmed γδ T cells in cancer
title_sort γδ T cells in cancer
author Coffelt, Seth B.
author_facet Coffelt, Seth B.
Kabelitz, Dieter
Silva-Santos, Bruno
Kuball, Jurgen
Born, Willi
Bank, Ilan
author_role author
author2 Kabelitz, Dieter
Silva-Santos, Bruno
Kuball, Jurgen
Born, Willi
Bank, Ilan
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Coffelt, Seth B.
Kabelitz, Dieter
Silva-Santos, Bruno
Kuball, Jurgen
Born, Willi
Bank, Ilan
dc.subject.por.fl_str_mv Bisphoshonates
Butyrophilin
Cancer
Immunotherapy
γδ T cells
topic Bisphoshonates
Butyrophilin
Cancer
Immunotherapy
γδ T cells
description Copyright © 2020 Coffelt, Kabelitz, Silva-Santos, Kuball, Born and Bank. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-04-06T12:46:40Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/47254
url http://hdl.handle.net/10451/47254
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Front Immunol. 2020 Nov 20;11:602411
10.3389/fimmu.2020.602411
1664-3224
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers
publisher.none.fl_str_mv Frontiers
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134539158650880

Registros relacionados